Literature DB >> 1933878

Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells.

C R Chitambar1, J Narasimhan, J Guy, D S Sem, W J O'Brien.   

Abstract

Our previous studies of the mechanism of cell growth inhibition by gallium have suggested that the block in cellular iron uptake induced by transferrin-gallium results in an inhibition of the iron-dependent M2 subunit of ribonucleotide reductase. However, it is not known whether the inhibitory effect of gallium on ribonucleotide reductase is solely the result of limiting iron availability for enzyme activity or whether a direct effect of intracellular gallium on the enzyme is also involved. In the present study, utilizing a cell-free assay, we show that gallium nitrate directly inhibits CDP and ADP reductase activity. Inhibition of DNA synthesis by gallium nitrate thus appears to be due to a combination of a block in iron availability to ribonucleotide reductase and a direct inhibition of the enzyme by gallium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933878

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Gallium-containing anticancer compounds.

Authors:  Christopher R Chitambar
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

2.  Cytotoxic gallium complexes containing thiosemicarbazones derived from 9-anthraldehyde: Molecular docking with biomolecules.

Authors:  Floyd A Beckford; Alyssa Brock; Antonio Gonzalez-Sarrías; Navindra P Seeram
Journal:  J Mol Struct       Date:  2016-05-24       Impact factor: 3.196

3.  Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase.

Authors:  Christopher R Chitambar; Mona M Al-Gizawiy; Hisham S Alhajala; Kimberly R Pechman; Janine P Wereley; Robert Wujek; Paul A Clark; John S Kuo; William E Antholine; Kathleen M Schmainda
Journal:  Mol Cancer Ther       Date:  2018-03-28       Impact factor: 6.261

4.  An in vitro enzymatic assay to measure transcription inhibition by gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles.

Authors:  Grace Y Tang; Melanie A Pribisko; Ryan K Henning; Punnajit Lim; John Termini; Harry B Gray; Robert H Grubbs
Journal:  J Vis Exp       Date:  2015-03-18       Impact factor: 1.355

5.  Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3.

Authors:  Y Ido; N Muto; A Inada; J Kohroki; M Mano; T Odani; N Itoh; K Yamamoto; K Tanaka
Journal:  Cell Prolif       Date:  1999-02       Impact factor: 6.831

Review 6.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

Review 7.  Medical applications and toxicities of gallium compounds.

Authors:  Christopher R Chitambar
Journal:  Int J Environ Res Public Health       Date:  2010-05-10       Impact factor: 3.390

8.  Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells.

Authors:  Meiying Yang; Christopher R Chitambar
Journal:  Free Radic Biol Med       Date:  2008-06-14       Impact factor: 7.376

9.  Modulation of transferrin receptor mRNA by transferrin-gallium in human myeloid HL60 and lymphoid CCRF-CEM leukaemic cells.

Authors:  R Ul-Haq; C R Chitambar
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

10.  4-N-Alkanoyl and 4-N-alkyl gemcitabine analogues with NOTA chelators for 68-gallium labelling.

Authors:  Jesse Pulido; Maria de Cabrera; Adam J Sobczak; Alejandro Amor-Coarasa; Anthony J McGoron; Stanislaw F Wnuk
Journal:  Bioorg Med Chem       Date:  2018-10-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.